Try our mobile app
New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS® (mavacamten) for patients with symptomatic obstructive HCM
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania. Clinical trial data to be featured include new analyses of the effectiveness of CAMZYOS® (mavacamten) in patients with and without gene variants from the Phase 3 EXPLORER-HCM study, as well as new real-world analyses of patients with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) receiving CAMZYOS in clinical practice.
The Bristol Myers Squibb-Pfizer Alliance will also provide new data describing disparity in oral anticoagulant utilization patterns among commercially insured patients with non-valvular atrial fibrillation (NVAF) with high stroke risk by geographic region and race in the U.S.
“We’re looking forward to the opportunity to showcase new clinical and real-world analyses across our cardiovascular franchise, which support our commitment to develop medicines that address the global burden of cardiovascular disease,” said Roland Chen, Senior Vice President, Head of Development, Immunology, Cardiovascular & Neurology. “These data at the AHA Scientific Sessions continue to demonstrate the benefit that treatment with CAMZYOS provides for a broad spectrum of patients with symptomatic obstructive hypertrophic cardiomyopathy in clinical studies as well as in clinical practice.”
Key presentations include:
Summary of Presentations Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at AHA Congress 2023 include:
Abstract Title | Primary Author | Type/# | Session Title | Time (EST) | |
Saturday, November 11, 2023 | |||||
Real-World Adherence to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States | Masri, A. | Poster – 3002 | Drugs, Drugs, and More Drugs: New Pharmacologic Insights in Heart Failure Management | 11:30 AM – 12:45 PM
| |
Disparities in Speed of Diagnosis of Hypertrophic Cardiomyopathy in the United States | Masri, A. | Rapid Oral Fire – 515 | Exciting Developments in Heart Failure Diagnosis and Evaluation | 12:10 PM – 12:15 PM
| |
Healthcare Resource Utilization and Costs Associated With New York Heart Association Functional Class in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States | Wang, Y. | Poster – 3116 | Socioeconomic Disparities and Cardiovascular Health | 3:00 PM – 4:15 PM
| |
Biomarker Profile of Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction or Reduced Ejection Fraction: Insights From the ARISTOTLE Trial* | Pol, T. | Poster - 1059 | HFpEF | 3:00 PM – 4:15 PM | |
Sunday, November 12, 2023 | |||||
Real-World Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: A US Single Center Experience | Reza, N. | Poster – 2160 | Hypertrophic, Obstructive, and Takotsubo Cardiomyopathy: From Genetics to Outcomes | 11:30 AM – 12:45 PM
| |
Monday, November 13, 2023 | |||||
Relationship Between the Kansas City Cardiomyopathy Questionnaire Score and New York Heart Association Class in Patients With Hypertrophic Cardiomyopathy: Insights from EXPLORER-HCM | Sherrod, C. | Poster - 2194 | Game Changing Disease Management in Hypertrophic, Amyloid, and Cardiomyopathy Care | 10:30 AM –11:45 AM
| |
Geographic and Racial Variation in Oral Anticoagulant Treatment Among Commercially Insured Patients With Non-Valvular Atrial Fibrillation in the United States* | Atwater, B. | E-poster - 2146 | Treatment of Arrhythmias: Risk Stratification for Stroke and Stroke Reduction Therapies
| 1:30 PM – 2:45 PM
| |
Response to Mavacamten by Sarcomere Gene Mutation Status in EXPLORER-HCM | Ho, C. | Rapid fire oral – 551
| The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms | 1:50 PM – 1:55 PM
| |
The Effect of Mavacamten Treatment on Hemolysis Biomarkers in Patients With Obstructive Hypertrophic Cardiomyopathy in the EXPLORER-HCM Study | Wang, Z. | Rapid fire oral – 553 | The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms | 2:10 PM – 2:15 PM
| |
*Sponsored by the Bristol Myers Squibb-Pfizer Alliance
About CAMZYOS®(mavacamten) CAMZYOS® (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms, and in the European Union, indicated for the treatment of symptomatic (NYHA, class II-III) obstructive HCM in adult patients. It has also received regulatory approvals on five continents including in Argentina, Australia, Brazil, Canada, Great Britain, Israel, Macau, Singapore, South Korea, and Switzerland. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HEART FAILURE
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF
